The Future of GLP-1 Drugs and AI Medicine, With Eli Lilly CEO David Ricks

The GLP-1 drug revolution has taken the medicine world by storm. I’ve done several episodes on the science of GLP-1s. But we’ve never done an episode like this before, where we talk to one of the most important people in charge of guiding the GLP-1 drug revolution.

Our guest is Dave Ricks, the CEO of Eli Lilly, the largest pharmaceutical company in the world. First we talk about what makes the GLP-1 drug category special and the science that Lilly is doing to improve these drugs. Then, we talk about the pharmaceutical industry more broadly. How it works. How it could work better. And I don’t shy away from the question that I think Pharma CEOs need to take much more seriously: If the pharmaceutical industry is theoretically more devoted than any other economic category to saving people’s lives, why do Americans distrust it more than any other industry in the entire economy?

Subscribe to our YouTube channel here: https://www.youtube.com/@PlainEnglishwithDerekThompson

If you have questions, observations, or ideas for future episodes, email us at PlainEnglish@Spotify.com.

Host: Derek Thompson
Guest: David Ricks
Producer: Devon Baroldi

Learn more about your ad choices. Visit podcastchoices.com/adchoices